DOCKET NO.: 00100.US1

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of:

Vogeli et al.

Serial No.: 09/794,058

Filing Date: March 8, 2001

ing Date. Water 6, 2001

Group Art Unit: Not Yet Assigned

Examiner: Not Yet Assigned

NOVEL G PROTEIN-COUPLED RECEPTORS

DATE OF DEPOSIT: June 6, ZOOI

I HEREBY CERTIFY THAT THIS PAPER IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE AS FIRST CLASS MAIL, POSTAGE PREPAID ON THE DATE INDICATED ABOVE AND IS ADDRESSED TO THE ASSISTANT COMMISSIONER FOR PATENTS, WASHINGTON, DC 20231.

TYPEI NAME: Gwilym J.O. Attwell

Assistant Commissioner for Patents Washington DC 20231

Dear Sir:

 \boxtimes

INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §§1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 C.F.R. §1.56(b).

In accordance with §1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified application, within three months of the date of entry into the national stage of the above identified application as set forth in §1.491, before the mailing date of a first Office Action on the merits of the above-identified application, or before the mailing date of a first office action after the filing of request for continued examination under §1.114, no additional fee is required.

	In accordance with §1.129(a), this Information Disclosure Statement is being	
	filed in connection with \square the first or \square second After Final Submission,	
	therefore:	
	☐ Certification in Accordance with §1.97(e) is attached; or	
	The fee of $$180.00$ as set forth in $$1.17(p)$ is attached.	
	In accordance with §1.97(c), this Information Disclosure Statement is being filed	
	after the period set forth in §1.97(b) above but before the mailing date of either	
	a Final Action under §1.113 or a Notice of Allowance under §1.311, or before an	
	action that otherwise closes prosecution in the application, therefore:	
	☐ Certification in Accordance with §1.97(e) is attached; or	
	\square The fee of \$\frac{\$180.00}{}\$ as set forth in \$1.17(p) is attached.	
	In accordance with §1.97(d), this Information Disclosure Statement is being filed	
•	after the mailing date of either a Final Action under §1.113 or a Notice of	
	Allowance under §1.311 but before, or simultaneously with, the payment of the	
	Issue Fee, therefore included are: Certification in Accordance with §1.97(e); and	
	the submission fee of \$\frac{\\$180.00}{}\$ as set forth in \$1.17(p).	
	Copies of each of the references listed on the attached Form PTO-1449 are	
	enclosed herewith.	
\boxtimes	Copies of references listed on the attached Form PTO-1449 are enclosed herewith	
	EXCEPT THAT:	
	In view of the voluminous nature of references HL-IA , and the likelihood	
	that these references are available to the Examiner, copies are not	
	enclosed herewith.	
	☐ In accordance with §1.98(d), copies of the following references listed on	

the attached Form PTO-1449 are not enclosed herewith because they were previously cited by or submitted to the U.S. Patent and Trademark Office in patent application(s) for which a claim for priority under 35 U.S.C.§120 have been made in the instant application:

Copies of references [list as appropriate] listed on the attached Form

PTO-1449 were previously cited by or submitted to the Patent and

Trademark Office in prior application Serial No. , filed .

☐ If any of the foregoing publications are not available to the Examiner, Applicant will endeavor to supply copies at the Examiner's request.

Please charge any deficiency or credit any overpayment to Deposit Account No. 23-3050. This form is submitted in duplicate.

English language abstracts have been provided for those listed references which are not in the English language.

Date: June 6, 2001

wilym J.O. Attwell

WOODCOCK WASHBURN KURTZ MACKIEWICZ & NORRIS LLP One Liberty Place - 46th Floor Philadelphia, PA 19103

Telephone: (215) 568-3100 Facsimile: (215) 568-3439

© 2000 WWKMN



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

7/80/944

In Re Application of:

Vogeli et al.

Filing Date: March 8, 2001 **Examiner: Not Yet Assigned**

NOVEL G PROTEIN-COUPLED RECEPTORS

DATE OF DEPOSIT: June 6, ZOOI

Group Art Unit: Not Yet Assigned

I HEREBY CERTIFY THAT THIS PAPER IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE AS FIRST CLASS MAIL, POSTAGE PREPAID ON THE DATE INDICATED ABOVE AND IS ADDRESSED TO THE ASSISTANT COMMISSIONER FOR PATENTS,

WASHINGTON, DC 20231.

NAME: Gwilym J.O. Attwell STRATION NO.: 45,449

Assistant Commissioner for Patents Washington DC 20231

Dear Sir:

X

INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §§1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 C.F.R. §1.56(b).

> In accordance with §1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified application, within three months of the date of entry into the national stage of the above identified application as set forth in §1.491, before the mailing date of a first Office Action on the merits of the above-identified application, or before the mailing date of a first office action after the filing of request for continued examination under §1.114, no additional fee is required.

	In accordance with §1.129(a), this Information Disclosure Statement is being		
	filed	in connection with \square the first or \square second After Final Submission,	
	there	fore:	
		Certification in Accordance with §1.97(e) is attached; or	
		The fee of \$180.00 as set forth in §1.17(p) is attached.	
	In acc	cordance with §1.97(c), this Information Disclosure Statement is being filed	
	after	the period set forth in §1.97(b) above but before the mailing date of either	
	a Fina	al Action under §1.113 or a Notice of Allowance under §1.311, or before an	
	action	that otherwise closes prosecution in the application, therefore:	
		☐ Certification in Accordance with §1.97(e) is attached; or	
		The fee of $$180.00$ as set forth in $$1.17(p)$ is attached.	
	In acc	cordance with §1.97(d), this Information Disclosure Statement is being filed	
	after	the mailing date of either a Final Action under §1.113 or a Notice of	
	Allov	vance under §1.311 but before, or simultaneously with, the payment of the	
	Issue	Fee, therefore included are: Certification in Accordance with §1.97(e); and	
	the su	abmission fee of \$180.00 as set forth in §1.17(p).	
	Copie	es of each of the references listed on the attached Form PTO-1449 are	
	enclo	sed herewith.	
\boxtimes	Copie	es of references listed on the attached Form PTO-1449 are enclosed herewith	
	EXC	EPT THAT:	
	\boxtimes	In view of the voluminous nature of references HL-IA , and the likelihood	
		that these references are available to the Examiner, copies are not	
		enclosed herewith.	
		In accordance with §1.98(d), copies of the following references listed on	

the attached Form PTO-1449 are not enclosed herewith because they were previously cited by or submitted to the U.S. Patent and Trademark Office in patent application(s) for which a claim for priority under 35 U.S.C.§120 have been made in the instant application:

- Copies of references [list as appropriate] listed on the attached Form

 PTO-1449 were previously cited by or submitted to the Patent and

 Trademark Office in prior application Serial No. , filed .
 - ☐ If any of the foregoing publications are not available to the Examiner, Applicant will endeavor to supply copies at the Examiner's request.

Please charge any deficiency or credit any overpayment to Deposit Account No. 23-3050. This form is submitted in duplicate.

English language abstracts have been provided for those listed references which are not in the English language.

Date: June 6, 2001

Gwilym J.O. Attwell Registration No. 45,449

WOODCOCK WASHBURN KURTZ MACKIEWICZ & NORRIS LLP One Liberty Place - 46th Floor Philadelphia, PA 19103 Telephone: (215) 568-3100

Facsimile: (215) 568-3439

© 2000 WWKMN

PATE	TE TRADER		Sheet 1 of 23
Form	PTO-1449 Modified	Docket No. 00100.US1	Serial No. 09/194,058
	List of Patent and Publications Cited by Applicant (Use several sheets if necessary)		
1	Department of Commerce at and Trademark Office	Filing Date March 8, 2001	Group Not Yet Assigned
ОТНЕ	R DOCUMENTS (Including Author	r, Title, Date, Pertinen	t Pages, Etc.)
AA	Akane et al., "Direct Dideoxy Sequen PCR", Biotechniques, 1994, Vol. 16	_	by Ligation-Mediated
AB (Allen et al., "Modulation of CD4 by pp. 141-156	Suramin", Clin. Exp. Im	munol., 1993 , Vol. 91,
AC (Altschul et al., "Gapped BLAST and PSI-BLAST: a new generation of protein database search programs," <i>Nucl. Acids Res.</i> , 1997 , <i>25(17)</i> , 3389-3402		
AD	Altschul et al., "Basic Local Alignme 410	ent Search Tool," J. Mod	d. Biol., 1990, 215, 403-
AE (American Veterinary Medical Association, Report of the American Veterinary Medical Assoc., Panel on Euthanasia, Journal of American Veterinary Medical Assoc., 1993, 202, 229-249		
AF (Anafi et al., "Tyrphostin-Induced Infinduces K562 to Differentiate", Block		
AG (Anderson, "Human Gene Therapy", <i>Nature</i> , 1998 , Suppl. To Vol. 392, No. 3379, pp. 25-20		
AH	Anderson, W. F., "Human gene therapy," Science, 1992, 256, 808-813		
AI i	Aujame et al., "High Affinity Human Antibodies by Phage Display", <i>Human Antibodies</i> , 1979 , Vol. 8, No. 4, pp. 155-168		
AJ (Aukrust et al., "Enhanced Levels of Soluble and Membrane-Bound CD40 Ligand in Patients with Unstable Angina. Possible Reflection of T Lymphocyte and Platelet Involvement in the Pathogenesis of Acute Coronary Syndromes", <i>Circulation</i> , 1999, Vol. 100, pp. 614-620		
AK	Ausubel, et al. (Eds.), "Chapter 6, Screening of recombinant DNA libraries," Current Protocols in Molecular Biology, 1994, John Wiley & Sons, 6.0.3-6.4.10		

DATE CONSIDERED

EXAMINER

OT PE SOLGE

0 30 9 44 Sheet 2 of 23

ATENT 8	TRADE		Sheet 2 of 23
Form	PTO-1449 Modified	Docket No. 00100.US1	Serial No. 99/794,958
	f Patent and Publications Cited by Applicant everal sheets if necessary)	Applicant Vogeli et al.	
	Department of Commerce nt and Trademark Office	Filing Date March 8, 2001	Group Not Yet Assigned
ОТН	ER DOCUMENTS (Including Author	r, Title, Date, Pertinen	t Pages, Etc.)
AL /	Baindur et al.," Selective fluorescent Dev. Res., 1994, 33, 373-398	ligands for pharmacolo	gical receptors," Drug
AM	Baker et al., "Induction of Acetylchol Beads. Implication of an Endogenous Sci., 1992, Vol. 102, pp. 543-555	line Receptor Clustering Muscle-derived Signal	g by Native Polystyrene ling System", <i>J. Cell</i>
AN /	Barker et al., "In-Vitro Activity of Non-glutamate Containing Quinazoline-based Thymidylate Synthase Inhibitors", <i>Proc. of Am. Assoc. for Cancer Res.</i> , 1991 , Vol. 32, page 327		
AO	Bauer et al., "A genetic enrichment for mutations constructed by oligodeoxynucleotide-directed mutagenesis," <i>Gene</i> , 1985 , <i>37</i> , 73-81		
AP	Benoist et al., "In vivo sequence requi Nature, 1981, 290, 304-310	irements of the SV40 ea	rly promoter region,"
AQ	Bertino, Cancer Res., "Toward Impro Richard and Hinda Rosenthal Founda	oved Selectivity in Canc tion Award Lecture", 1	er Chemotherapy: The 979 , Vol. 3, pp. 293-304
AR	Bilder et al., "Tyrphostins Inhibit PDe Early Events in Smooth Muscle Cells 6143:C721-C730	GF-induced DNA Synth, ", Amer. Physiol. Soc.,	nesis and Associated 1991, pp. 6363-
AS	Birney, E., et al., "PairWise and SearchWise: finding the optimal alignment in a simultaneous comparison of a protein profile against all DNA translation frames," Nucleic Acids Res., 1996, 24(14), 2730-2739		
AT /	Blouin, J-L. et al., "Schizophrenia sus 8p21," Nature Genetics, Sept. 1988, 2	sceptibility loci on chron 20, 70-73	nosomes 13q32 and
AU	AU Bohm, S. K., et al., "Regulatory mechanisms that modulate signalling by G-protein-coupled receptors," Biochem. J., 1997, 322, 1-18		
EXAMINER		DATE CONSIDERE	D



09 88 944 Sheet 3 of 23

Form	PTO-1449 Modified	Docket No. 00100.US1	Serial No. -09/ 794,058 -
	List of Patent and Publications Cited by Applicant (Use several sheets if necessary)		
1	epartment of Commerce t and Trademark Office	Filing Date March 8, 2001	Group Not Yet Assigned
ОТНЕ	R DOCUMENTS (Including Author	, Title, Date, Pertinen	t Pages, Etc.)
AV	protein-coupled receptors for high thi	nonseparation binding and functional assays for G throughput screening: Pharmacological I CCR5 receptor on FlashPlate®," J. Biomolecular	
AW (family of protein-serine/threonine kinases that are ated in response to insulin and NGF," Cell, 1991,	
AX /	Bowie, J. U., et al., "Deciphering the Message in Protein Sequences: Tolerance to Amino Acid Substitutions," <i>Science</i> , March 1990, 247, 1306-1310		-
AY		cular Cloning and Expression of an Avian G Protein- Molecular Pharmacology, 1997, 52, 928-934	
AZ (AZ Breeden, L., et al., "Regulation of the yeast HO gene," Cold Spring Harb. Symp. Quant. Biol., 1985, 50, Vol. 1, Molecular Biology of Development, 643-650		
BA (Bruggemann, M., et al., "Production mice," Curr. Opin. Biotechnol., 1997		ertoires in transgenic
BB /	Bruggemann, M., et al., "Strategies for transgenic mice," <i>Immunol. Today</i> , 1	_	tibody repertoires in
BC (BC Brunton, V. G., et al., Proceedings of Amer. Assoc. Cancer Res., No. 3335, 1992, 33		Res., No. 3335, 1992 , <i>33</i> ,
BD (BD (Bryckaert, M., et al., "Inhibition of platelet-derived growth factor-induced mitogenesis and tyrosine kinase activity in cultured bond marrow fibroblasts by tyrphostins," Experimental Cell Research, 1992, 199, 255-261		rrow fibroblasts by
BE i	BE Brzustowicz, L. M., et al., "Linkage of Familial Schizophrenia to Chromosome 13q32," Am. J. Hum. Genet., 1999, 65, 1096-1103		
EXAMINER		DATE CONSIDERE	ED

Sheet 4 of 23

Form	PTO 449 Modified	Docket No. 00100.US1	Serial No. 09/794,05 8
	Patent and Publications Cited by Applicant veral sheets if necessary)	Applicant Vogeli et al.	
	epartment of Commerce t and Trademark Office	Filing Date March 8, 2001	Group Not Yet Assigned
ОТНЕ	R DOCUMENTS (Including Author	r, Title, Date, Pertinen	t Pages, Etc.)
BF /	Burke, T. R., et al., "Bicyclic comportyrosine kinase p56 ^{ick} ," J. Med. Chem.		
BG (Burke, T. R., et al., "Arylamides of h kinaseinhibitors," Bio Organic Med. C		
вн (Cane, D. E., et al., "Harnessing the Biosynthetic Code: Combinations, Permutations and Mutations," Science, Oct. 1998, 282, 63-68		
BI (Cao, Q., et al., "Suggestive Evidence for a Schizophrenia Susceptibility Locus on Chromosome 6q and a Confirmation in an Independent Series of Pedigrees," <i>Genomics</i> , 1997 , <i>43</i> , 1-8		
BJ (Capecchi, M. R., "Altering the genome by homologous recombination," <i>Science</i> , 1989 , <i>244</i> , 1288-1292		mbination," Science,
BK (Chambers, R. C., et al., "Thrombin stimulates fibroblast procollagen production via proteolytic activation of protease-activated receptor 1," <i>Biochem J.</i> , 1998 , <i>333</i> , 121 127		
BL (Choo, Y., et al., "Promoter-specific a bacteriophage-selected zinc fingers,"	0 1	•
BM ₍	Cicala, C., et al., "Bronchoconstrictor activating peptide in guinea-pigs in v		•
BN (Cirino, G., et al., "Thrombin function activation of its receptor," J. Exp. Me	-	nediator through
во	BO (Colotta, F., et al., "Expression of monocyte chemotactic protein-1 by monocytes endothelial cells exposed to thrombin," Am. J. Pathol, 1994, 144, 975-985		•
ВР	BP Conklin, B. R., et al., "Substitution of three amino acids switches receptor specific of $G_q\alpha$ to that of $G_i\alpha$," Nature, 1993, 363, 274-276		
EXAMINER		DATE CONSIDERE	ZD

09 80 944 Sheet 5 of 23

Form	PFO-1449 Modified	Docket No. 00100.US1	Serial No. 09/794,058
(Patent and Publications Cited by Applicant everal sheets if necessary)	Applicant Vogeli et al.	
	epartment of Commerce t and Trademark Office	Filing Date March 8, 2001	Group Not Yet Assigned
ОТНЕ	R DOCUMENTS (Including Author	r, Title, Date, Pertinen	t Pages, Etc.)
BQ	Cosman, D., et al., "High Level Stable in Mouse Cells Generates only Low Immunol., 1986, 23(9), 935-941		
BR (Cosman, D., et al., "Cloning, sequence receptor," <i>Nature</i> , 1984 , <i>312</i> , 768-77	-	man interleukin-2
BS (Craik, C. S., "Use of Oligonucletides Jan/Feb 1985, 12-19	for Site-Specific Muta	genesis," BioTechniques,
BT (Curtin, N. J., et al., "Inhibition of the growth of human hepatocellular carcinoma in vitro and in athymic mice by a quinazoline inhibitor of thymidylate synthase, CB3717," J. Cancer, 1986, 53, 361-368		
BU /	Dayoff, in Atlas of Protein Sequence and Structure, 1972, National Biochemical Research Foundation, Washington, D.C., 5, 124		
BV (DiCuccio, M. N., et al., "A functiona human hematopoietic progenitor cell	-	
BW ₍	BW Dolle, R. E., et al., "5,7-dimethoxy-3-(4-pyridinyl)quinoline is a potent and selective inhibitor of human vascular β-type platelet-derived growth factor receptor tyrosine kinase," J. Med. Chem., 1994, 37, 2627-2629		
BX (BX Dong, Z., et al., "Activation of tumoricidal properties in macrophages by lipopolysaccharide requirements protein-tyrosine kinase activity," J. Leukocyte Biology, 1993, 53, 53-60		
BY	BY Dong, Z., et al., "Protein tyrosine kinase inhibitors decrease induction of nitric oxid synthase activity in lipopolysaccharide-responsive and lipopolysaccharide-nonresponsive murine macrophages," J. Immunol., 1993, 151(5), 2717-2724		olysaccharide-
BZ	Donovan, F. M., et al., "Thrombin in astrocytes via a pathway requiring ty 1997, 17(14), 5316-5326		
EXAMINER		DATE CONSIDER	E D

09/801944 Sheet 6 of 23 Form PTO-1449 Modified Docket No. Serial No. 00100.US1 09/794,058 List of Patent and Publications **Applicant** Cited by Applicant Vogeli et al. (Use several sheets if necessary) U.S. Department of Commerce Filing Date Group Patent and Trademark Office March 8, 2001 Not Yet Assigned OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) CA Dooley, C. T., et al., "Binding and in vitro activities of peptides with high affinity for the nociceptin/orphanin FQ receptor, ORL1," J. Pharmacology and Experimental Therapeutics, 1997, 283(2), 735-741 CB Douglas, A. M., et al., "Direct sequencing of double-stranded PCR products incorporating a chemiluminescent detection procedure," Biotechniques, 1993, 14, 824-828 \mathbf{CC} Drmanac, R., et al., "DNA Sequence Determination by Hybridization A Strategy for Efficient Large-Scale Sequencing," Nature Biotechnology, 1998, 16, 54-58 CD Drmanac, S., et al., "Accurate sequencing by hybridization for DNA diagnostics and individual genomics," Science, June 1993, 260, 1649-1652 CE Dunlop, J., et al., "Characterization of 5-HT_{1A} receptor functional coupling in cells expressing the human 5-HT_{1A} receptor as assessed with the cytosensor microphysiometer," J. Pharmacological and Toxicological Methods, 1998, 40(1), 47-CF / Fernandes, D. J., et al., "Biochemical and antitumor effects of 5,8dideazaisopteroylglutamate, a unique quinazoline inhibitor of thymidylate synthase," Cancer Research, 1983, 43, 1117-1123 CG/ Ferris, J. P., et al., "Synthesis of Quinazoline Nucleosides from Ribose and Anthranilonitrile. Application of Phase-Transfer Catalysis in Nucleoside Synthesis," J. Org. Chem., 1979, 44(2), 173-178

EXAMINER

CH

CI /

CJ

Nature, 1989, 340, 245-246

Trends in Genetics, 1994, 10, 286-292

Natl. Acad. Sci. USA, 1983, 80, 1579-1583

DATE CONSIDERED

Fields, S., et al., "A novel genetic system to detect protein-protein interactions,"

Fields, S., et al., "The two-hybrid system: an assay for protein-protein interactions,"

Fischer, S. G., et al., "DNA fragments differing by single base-pair substitutions are separated in denaturing gradient gels: Correspondence with melting theory," *Proc.*

/c	IN THE COME	E 4CTAG
In ,	JUN O	James 1
PATENT & F	TALLET THE	TRACEMENT

Sheet 7 of 23

Form	Form PTO-1449 Modified List of Patent and Publications Cited by Applicant (Use several sheets if necessary)		Serial No. 09/794,058	
C				
	epartment of Commerce t and Trademark Office	Filing Date March 8, 2001	Group Not Yet Assigned	
OTHE	R DOCUMENTS (Including Author	r, Title, Date, Pertinen	t Pages, Etc.)	
CK (Foote, J., et al., Antibody framework hypervariable loops," J. Mol. Biol., 1		conformation of the	
CL _/	Frandsen, E. K., et al., "A simple ultrand CMP in tissues," Life Sciences, 1		he assay of cyclic AMP	
CM /	Friedmann, T., "Progress toward hum 1281	dmann, T., "Progress toward human gene therapy," Science, 1989, 244, 1275-1		
CN	Fry, D.W., et al., "A specific inhibitor of the epidermal growth factor receptor tyrosine kinase," <i>Science</i> , 1994 , <i>265</i> , 1093-1095			
co	Gazit, A., et al., "Tyrphostins I: Synthesis and biological activity of protein tyrosine kinase inhibitors," <i>J. Med. Chem.</i> , 1989 , <i>32</i> , 2344-2352			
CP (s. 3. Structure-activity relationship studies of α-nonitrile 5-S-aryltyrphostins," J. Med. Chem., 1993, 36,		
CQ (George, S. E., et al., "Evaluation of a an alternative to measuring cAMP ac 2(4), 235-240			
CR	Gerhardt, C. C., et al., "Functional chreceptors," Eur. J. Pharmacology, 19		ogously expressed 5-HT	
CS (Gill, J. S., et al., "Thrombin induced inhibition of neurite outgrowth from dorsal root ganglion neurons," <i>Brain Res.</i> , 1998 , 797, 321-327			
CT (Grabham, P., et al., Thrombin receptor activation stimulates astrocyte proliferation and reversal of stellation by distinct pathways: involvement of tyrosine phosphorylation," J. Neurochem, 1995, 64, 583-591			
CU	Greisman, H. A., et al., "A general st proteins for diverse DNA target sites	. .		
EXAMINER		DATE CONSIDER	ED	

OIP E TORENTE

Sheet 8 of 23

	PTO-1449 Modified	Docket No. 00100.US1	Serial No. 09/794,058
	List of Patent and Publications Cited by Applicant (Use several sheets if necessary)		
L	epartment of Commerce t and Trademark Office	Filing Date March 8, 2001	Group Not Yet Assigned
ОТНЕ	R DOCUMENTS (Including Author	r, Title, Date, Pertinen	t Pages, Etc.)
cv	Guan, X. M., et al., "Enhancement of membrane protein following introduce <i>Chem.</i> , 1992 , <i>267</i> , 21995-21998		
CW /	Guerrero, F. D., "Transcriptional Exp Receptor Gene From Stable Fly ¹ ," Pe		
CX (n stimulates contraction of human bronchial rings by receptors," Am J. Physiol, 1999, 277, L22-L29	
CY	Regulation of a Novel Receptor from to Members of the Thyroid-stimulating	ing, Genomic Organization, and Developmental om <i>Drosophila melanogaster</i> Structurally Related ating Hormone, Follicle-stimulating Hormone, dotropin Receptor Family from Mammals*," <i>The J.</i> 2(2), 1002-1010	
CZ/	Henikoff, S., et al., "Amino acid subs Natl. Acad. Sci. USA, 1992, 89, 1091	S., et al., "Amino acid substitution matrices from protein blocks," <i>Proc. l. Sci. USA</i> , 1992 , <i>89</i> , 10915-10919	
DA (Hill, D. C., "Trends in development of rapid discovery of novel drugs," Cur.	U U I	
рв (Hinuma, S., et al., "A prolactin-release 272-276	sing peptide in the brain	n," Nature, 1998 , 393,
DC /	Hodgson, J., "Receptor screening and the search for new pharmacteuticals," <i>Bio/Technology</i> , 1992 , <i>10</i> , 973-980		rmacteuticals,"
DD /	Hoffman, M., et al., "Thrombin enhances monocyte secretion of tumor necrosis factor and interleukin-1 beta by two distinct mechanisms," <i>Blood Cells Mol Dis</i> , 1995 , <i>21</i> , 156-167		
DE /	Hoogenboom H. R., "Designing and optimizing library selection strategies for generating high-affinity antibodies," <i>TIBTECH</i> , 1997 , <i>15</i> , 62-70		
DF /	Huse, W. D., et al., "Generation of a Immunoglobulin Repertoire in Phage	_	
EXAMINER	EXAMINER DATE CONSIDERED		

OLD E 10'50' SERVED

EXAMINER

7) 9 | 80 | 944 Sheet 9 of 23

	un' s		Sheet 9 of 23	
Form	PEROS 449 Modified	Docket No. (00100.US1	Serial No. 09/794,05 8	
	List of Patent and Publications Cited by Applicant (Use several sheets if necessary)			
	Department of Commerce at and Trademark Office	Filing Date March 8, 2001	Group Not Yet Assigned	
ОТНЕ	CR DOCUMENTS (Including Author	r, Title, Date, Pertinen	t Pages, Etc.)	
DG /	inhibitor that is a potent inhibitor of L1210 tumor cell growth in vitro and in vivo: A			
DH/	Jayawickreme, C. K., et al., "Gene ex throughput screens, Current Opinion	-		
DI /	Jones, P. T., et al., "Replacing the conantibody with those from a mouse," A	-	<u> </u>	
DJ (•	Jones, T. R., et al., "Quinazoline Antifolates Inhibiting Thymidylate Synthase: Variation of the Amino Acid," <i>J. Med Chem.</i> , 1986 , <i>29</i> , 1114-1118		
DK (Kanterman, R. Y., et al., "Transfected D ₂ dopamine receptors mediate the potentiation of arachidonic acid release in chinese hamster ovary cells," <i>Molecular Pharmacology</i> , 1991 , <i>39</i> , 364-369			
DL (Karlin, S., et al., "Applications and st molecular sequences," <i>Proc. Natl. Ac</i>			
DM _/	Kaur, G., et al., "Tyrphostin induced growth inhibition: corelation with effect on p210 ^{bcr-abl} autokinase activity in K562 chronic myelogenous leukemia," <i>Anti-Cancer Drugs</i> , 1994 , <i>5</i> , 213-222			
DN	Kettleborough, C. A., et al., "Humanization of a mouse monoclonal antibody by CDR-grafting: the importance of framework residues on loop conformation," <i>Protein Engin.</i> , 1991, 4(7), 773-783			
DO (Kieleczawa, J., et al., "DNA sequencing by primer walking with strings of contiguous hexamers," <i>Science</i> , 1992 , <i>258</i> , 1787-1791			
DP	Kim, J., et al., "Design of TATA box regulation of gene expression," <i>Proc.</i>	<u> </u>	•	
DQ	King, M. J., et al., "Site-specific dephosphorylation and deactivation of the human insulin receptor tyrosine kinase by particulate and soluble phosphotyrosyl protein phosphatases," <i>Biochem. J.</i> , 1991, 275, 413-418			

DATE CONSIDERED

A/801944 Sheet 10 of 23

Form	RADO 1449 Modified	Docket No. 00100.US1	Serial No. 09/794,058
C	Patent and Publications Cited by Applicant everal sheets if necessary)	Applicant Vogeli et al.	
	epartment of Commerce and Trademark Office	Filing Date March 8, 2001	Group Not Yet Assigned
OTHE	R DOCUMENTS (Including Autho	r, Title, Date, Pertinen	t Pages, Etc.)
DR	Kobilka, B. K., "Amino and carboxy production and purification of a G pr 1995, 231(1), 269-271	l terminal modifications otein-coupled receptor,	s to facilitate the "Analytical Biochemistry,
DS _/	Kowal, D., et al., "A [35S]GTPγS bin receptor standards in chinese hamste metabotropic receptor subtypes 2 and	r ovary cell lines expres	sing the human
DT /	Kuntzweiler, T. A., et al., "Rapid ass acetylcholine receptors using calcium Research, 1998, 44(1), 14-20	t al., "Rapid assessment of ligand actions with nicotinic rs using calcium dynamics and FLIPR," <i>Drug Development</i>), 14-20	
DU,	Kuo, M., et al., "Effects of signalling transduction modulators on the transformed phenotypes in v-H-ras-transformed NIH 3T3 cells," <i>Cancer Letters</i> , 1993 , <i>74</i> , 197-202		
DV /	Lajiness et al., "D2 dopamine receptor stimulation of mitogenesis in transfected chinese hamster ovary cells: relationship to dopamine stimulation of tyrosine phosphorylations", <i>J. Pharm. Exp. Ther.</i> , 1993 , Vol. 267, No. 3, 1573-1581		
DW į			
DX	DX Lehninger, "Chapter 4, The amino acid building blocks of proteins," <i>Biochemistry</i> , 2 ⁿ Ed., 1975, Worth Publishers, Inc., New York, New York, 71-77		
DY	Lemus, et al., "Studies of extended quinone methides. Synthesis and physical studies of purine-like monofunctional and bifunctional imidazo[4,5-g]quinazoline reductive alkylating agents," J. Org. Chem., 1989, 54, 3511-3518		
DZ	Levitzki, A., "Tyrphostins: tyrosine kinase blockers as novel antiproliferative agents and dissectors of signal transduction," <i>The FASEB J.</i> , 1992 , <i>6</i> , 3275-3282		
EA l	Ley, K., et al., "Synthesen unter ver 415-522 (English abstract)	wendung von benzofure	oxan," Synthesis, 1975,
EXAMINER		DATE CONSIDER	ED

OIPE JUN 1 1 2001

Sheet 11 of 23

Form :	Promote Modified	Docket No. 00100.US1	Serial No. 09/794,058
C	Patent and Publications Cited by Applicant veral sheets if necessary)	Applicant Vogeli et al.	
	epartment of Commerce and Trademark Office	Filing Date March 8, 2001	Group Not Yet Assigned
OTHE	R DOCUMENTS (Including Author	r, Title, Date, Pertinen	t Pages, Etc.)
EB	Li, X-J., et al., "Cloning, heterologou Drosophila receptor for tachykinin-lii 3221-3229		
EC	Li, X-J., et al., "Cloning, Functional Neuropeptide Y Receptor from <i>Dross Chemistry</i> , 1992 , <i>267(1)</i> , 9-12		
ED /	Lin, A. H., et al., "The oxazolidinone eperezolid binds to the 50S ribosomal subunit and competes with binding of chloramphenicol and lincomycin," <i>Antimicrobial Agents and Chemotherapy</i> , 1997, 41(10), 2127-2131		
EE (Lin, M-W., et al., "Suggestive evidence for linkage of schizophrenia to markers on chromosome 13 in Caucasian but not Oriental populations," <i>Hum Genet</i> , 1997 , <i>99</i> , 417-420		
EF (Liu, Q., et al., "Design of polydactyl zinc-finger proteins for unique addressing with complex genomes," <i>Proc. Natl. Acad. Sci. USA</i> , 1997 , <i>94</i> , 5525-5530		
EG /	Luckow, V. A., et al., "High Level Expression of Nonfused Foreign Genes with Autographa californica Nuclear Polyhedrosis Virus Expression Vectors," Virology, 1989, 170, 31-39		
ЕН /	Luckow, V. A., et al., "Trends in the Bio/Technology, 1988, 6, 47-55	development of baculo	virus expression vectors,"
EI /	Lyall, R. M., et al., "Tyrphostins inhibit epidermal growth factor (EGF)-receptor tyrosine kinase activity in living cells and EGF-stimulated cell preliferation," <i>J. Biol. Chem.</i> , 1989 , <i>264</i> , 14503-14509		
EJ (MacLennan, A. J., et al., "Cloning and Characterization of a Putative G-Protein Coupled Receptor Potentially Involved in Development," <i>Molecular and Cellular Neurosciences</i> , 1994 , <i>5</i> , 201-209		
EK j	Maguire, M. P., et al., "A new series substituted quinoline derivatives," J.		
EXAMINER		DATE CONSIDERI	ED

09 801944 _____Shee+

Sheet	12 of 23
-------	----------

Form I	Form PTO-1449 Modified		Serial No. 09/794,058	
C	List of Patent and Publications Cited by Applicant (Use several sheets if necessary)			
	epartment of Commerce and Trademark Office	Filing Date March 8, 2001	Group Not Yet Assigned	
ОТНЕ	R DOCUMENTS (Including Author	r, Title, Date, Pertinen	t Pages, Etc.)	
	Maxam, A. M., et al., "Sequencing en cleavages", Meth. Enzymol., 1977, V		se-secific chemical	
EM	Maxwell, R. J., et al., "19F nuclear mavivo: The disposition of an antifolate in Medicine, 1991, 17, 189-196	agnetic resonance imagi anticancer drug in mice	ing of drug distribution in e," Magnetic Resonance	
	McColl, D. J., et al., "Structure-based design of an RNA-binding zinc finger", <i>Proc. Natl. Acad. Sci. (USA)</i> , 1997 , Vol. 96, 9521-9526			
EO [Miller, A. D., "Human gene therapy comes of age", Nature, 1992, Vol. 357, pp. 455			
EP [Mini, E., et al., "Cytotoxic effects of folate antagonists against methotrexate-resistant human leukemic lymphoblast CCRF-CEM cell lines," <i>Cancer Res.</i> , 1985 , <i>45</i> , 325-330			
EQ	Mirzabekov, A. D., "DNA sequencing and a diagnostic tool?", TIBTECH,		megasequencing method	
ER /	Monnier, D., et al., "NKD, a Develop Drosophila," <i>The J. of Biological Ch</i>	omentally Regulated Ta emistry, 1992, 267(2),	schykinin Receptor in 1298-1302	
ES (Morris, R., et al., "Thrombin receptor synovial tissue", Ann. Rheum. Dis.,			
ET	Morrison, et al., "Genetically engine (Eds.), Adv. Immunol., 1989, 44, 65-		s," Dixon, F.J., et al.	
EU (Murphy, A. J., et al., "From DNA to drugs: the orphan G-protein coupled receptors," Cur. Opinion Drug Disc. Dev., 1998, 1(2), 192-199			
EV	Myers, R. M., et al., "Detection of single base substitutions by ribonuclease cleavage at mismatches in RNA: DNA duplexes", <i>Science</i> , 1985 , Vol. 230,1242-1246			
EW	EW Myers, P., "Will combinatorial chemistry deliver real medicines," Curr. Opin. Biotechnology, 1997, 8, 701-707			
EXAMINER		DATE CONSIDER	ED	

OIPE COS

05/80 944 Sheet 13 of 23

Form	FTG-1449 Modified	Docket No. 00100.US1	Serial No. 0 9/794,0 58		
	f Patent and Publications Cited by Applicant everal sheets if necessary)	Applicant Vogeli et al.			
	Department of Commerce at and Trademark Office	Filing Date March 8, 2001	Group Not Yet Assigned		
ОТНЕ	ER DOCUMENTS (Including Author	r, Title, Date, Pertinen	t Pages, Etc.)		
EX/	Nakayama, G. R., "Microplate assays Drug Disc. Dev., 1998, 1, 85-91	for high-throughput sc	reening," Cur. Opinion		
EY /	Naldini, A., et al., "Thrombin modula peripheral lymphocytes," Cell Immun	ation of natural killer action, 1996 , <i>172</i> , 35-42	tivity in human		
EZ	Okayama, H., et al., "A cDNA clonin in mammalian cells," <i>Mol. Cell. Biol.</i>	g vector that permits ex, 1983, 3(2), 280-289	pression of cDNA inserts		
FA (Orita, M., et al., "Detection of polymorphisms of human DNA by gel electrophoresis as single-strand conformation polymorphisms," <i>Proc. Natl. Acad. Sci. USA</i> , 1989 , <i>86</i> , 2766-2770				
FB (Padlan, E. A., "A possible procedure for reducing the immunogenicity of antibody variable domains while preserving their ligand-binding properties," <i>Molecular Immunol.</i> , 1991 , 28(4/5), 489-498				
FC	Parodi, L. A., et al., "A consensus protransmembrane segments in proteins,"	cedure for predicting the Comput. Appl. Biosci.	ne location of α-helical 1994, 10(5), 527-535		
FD (Pastinen, T., et al., "Minisequencing: diagnostics on oligonucleotide arrays,	A specific tool for DNA " Genome Res., 1997, 7	A analysis and 7, 606-614		
FE	Pausch, M. H., "G-protein-coupled receptors in saccharomyces cerevisiae: high-throughput screening assays for drug discovery," <i>Trends in Biotechnology</i> , 1997 , <i>15</i> , 487-494				
FF _\	Pease, A. C., et al., "Light-generated oligonucleotide arrays for rapid DNA sequence analysis," <i>Proc. Natl. Acad. Sci. USA</i> , 1994 , <i>91</i> , 5022-5026				
FG (Peterson, G., et al., "Genistein and biochanin A inhibit the growth of human prostate cancer cells but not epidermal growth factor receptor tyrosine autophosphorylation," <i>The Prostate</i> , 1993, 22, 335-345				
EXAMINER	EXAMINER DATE CONSIDERED				

	2 20.	Sheet 14 of 23		
Form	Promate Modified	Docket No. 00100.US1	Serial No. 9944	
	f Patent and Publications Cited by Applicant everal sheets if necessary)	Applicant Vogeli et al.		
	Department of Commerce t and Trademark Office	Filing Date March 8, 2001	Group Not Yet Assigned	
ОТНЕ	R DOCUMENTS (Including Autho	r, Title, Date, Pertinen	t Pages, Etc.)	
FH	Phillips, S. D., et al., "Quino[1,2-c]q c]quinazolinium derivatives and the analogs of the antitumor benzol[c]ph 1980, 17(19), 1489-1596	related indazolo[2,3-a]q	uinoline derivatives as	
FI /	Pillemer, G., et al., "Insulin dependence of murine lymphoid T-cell leukemia," Cancer, 1992, 50, 80-85			
FJ /	FJ / Pindon, A., et al., "Thrombin-induced reversal if astricyte stellation is mediactivation of protein kinase C β -1," Eur. J. Biochem., 1998, 255, 766-774			
FK [/]	Posner, I., et al., "Kinetics of inhibition by tyrphostins of the tyrosine kinase act of the epidermal growth factor receptor and analysis," <i>Molecular Pharmacology</i> 1993 , <i>45</i> , 673-683			
FL /	Pulver, A. E., et al., "The Johns Hopkins University Collaborative Schizophrenia Study: An Epidemiologic-Genetic Approach to Test the Heterogeneity Hypothesis and Identify Schizophrenia Susceptibility Gene," Cold Spring Harbor Symposia on Quantitative Biology, ©1996, 61, 797-814			
FM	Rader, C., et al., "Phage display of co Biotechnol., 1997, 8, 503-508	ombinationial antibody	libraries," Curr. Opin.	
FN !	Ramsay, G., "DNA chips: state-of-th	e-art," Nature Biotechn	ology, 1999 , 16, 40-48	
FO (Reece, P. A., et al., "Pharmacokinetics of trimetrexate administered by five-day continuous infusion to patients with advanced cancer," <i>Cancer Research</i> , 1977 , 47(11), 2996-2999			
FP \	Reinsheid, R. K., et al., "Orphanin FQ: A neuropeptide that activates an opioidlike protein-coupled receptor," <i>Science</i> , 1995 , <i>270</i> , 792-794			
FQ	FQ Rendu, F., et al., "Inhibition of platelet activation by tyrosine kinase inhibitors," Bio Pharmacology, 1992, 44(5), 881-888			
EXAMINER		DATE CONSIDERE	CD	



Form	PTO-1449 Modified	Docket No. 00100.US1	Serial No.
Ċ	Patent and Publications Cited by Applicant veral sheets if necessary)	Applicant Vogeli et al.	
	epartment of Commerce and Trademark Office	Filing Date March 8, 2001	Group Not Yet Assigned
ОТНЕ	R DOCUMENTS (Including Author	r, Title, Date, Pertinen	t Pages, Etc.)
FR /	Riechmann, L., et al., "Reshaping hu 323-327	uman antibodies for the	rapy," <i>Nature</i> , 1988 , <i>332</i> ,
FS	Riesner, D., et al., "Temperature-gradient gel electrophoresis of nucleic acids: Analysis of conformational transitions, sequence variations, and protein-nucleic acinteractions," <i>Electrophoresis</i> , 1989 , <i>10</i> , 377-389		
FT (Roberts, E., et al., "Potassium permanganate and tetraethylammonium chloride are a safe and effective substitute for osmium tetroxide in solid-phase fluorescent chemica cleavage of mismatch," <i>Nucl. Acids Res.</i> , 1997, 25(16), 3377-3378		
FU(Rogers, M. V., "Light on high-throughput screening: fluorescence-based assay technologies," <i>Drug Discovery Today</i> , 1997 , <i>2</i> (4), 156-160		
FV (Rowley, G., et al., "Ultrarapid mutation detection by multiplex solid-phase chemical cleavage," <i>Genomics</i> , 1995 , <i>30</i> , 574-582		
FW (Saito, Y., et al., "Molecular characterization of the melanin-concentrating-hormone receptor," <i>Nature</i> , 1999 , <i>400</i> , 265-269		
FX (Sakurai, T., et al., "Orexins and orexin receptors: A family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior," <i>Cell</i> , 1998, 92, 573-585		
FY/	Sanger, F., et al., "DNA sequencing with chain-terminating inhibitors," <i>Proc. Natl. Acad. Sci. USA</i> , 1977 , <i>74</i> (12), 5463-5467		
FZ /	Sauro, M. D., et al., "Tyrphostin attenuates platelet-derived growth factor-induced contraction in aortic smooth muscle through inhibition of protein tyrosine kinase(s)," <i>J. Pharm. And Experimental Therapeutics</i> , 1993 , 267(3), 1119-1125		
GA/	Schafer, A. J., et al., "DNA variation and the future of human genetics," <i>Nature Biotechnology</i> , 1998 , <i>16</i> , 33-39		
GB /	Schroeder, K. S., et al., "FLIPR: A no optical screening," J. Biomolecular S		
EXAMINER		DATE CONSIDER	ED



	Sheet 10 01 23	
Docket No. 00100.US1	Serial No.	
Applicant Vogeli et al.		
Filing Date March 8, 2001	Group Not Yet Assigned	
or, Title, Date, Pertine	nt Pages, Etc.)	
nsive care unit (ICU) in	a medical oncology	
GD / Segal, D. J., et al., "Toward controlling gene expression at will: Selection and do of zine finger domains recognizing each of the 5'-GNN-3' DNA target sequences <i>Proc. Natl. Acad. Sci. USA</i> , 1999, 96, 2758-2763		
Shaw, S. H., et al., "A Genome-Wide Search for Schizophrenia Susceptibility Genes Amer. J. of Med. Genet. (Neuropsych. Genet.), 1998, 81, 364-376		
Shumaker, J. M., et al., "Mutation detection by solid phase primer extension," Hum Mutat., 1996, 7, 346-354		
Sikora, E., et al., "Quinazoline CB 3717 and CB 3703 inhibition of folate retention and metabolism in ehrlich ascites carcinoma cells and some organs of the host-mouse," <i>Cancer Letters</i> , 1984 , <i>23</i> , 289-295		
Sikora, E., et al., "Development of an assay for the estimation of N^{10} -propargyl-5,8 dideazafolic acid polyglutamates in tumor cells," <i>Analytical Biochemistry</i> , 1988 , 17 344-355		
opioid receptor-like (OF Neuroreport, 1996 , 7, 72	RL1) peptide-stimulated 9-733	
f biosequences," Adv. A	ppl. Math., 1981 , 2, 482-	
Smith-Swintosky, V. L., et al., "protease-activated receptor-2 (PAR-2_ is present in the rat hippocampus and is associated with neurodegeneration," <i>J. Neurocham</i> , 1997, 69, 1890-1896		
Sonnhammer, E., et al., "A hidden markov model for predicting transmembrane helices in protein sequences," Glasgow, J., et al. (Eds.), ISMB, 1998, 6, 175-182		
nt assay for agonist activated Biochemistry, 1997,	vity at potentially any G- 252, 115-126	
DATE CONSIDE	RED	
	Applicant Vogeli et al. Filing Date March 8, 2001 Tor, Title, Date, Pertiner Insive care unit (ICU) in anol. And Immunother., Ing gene expression at very each of the 5'-GNN-3' December of the Search for Schizophre of the Genet.), 1998, 81, 36 Idetection by solid phase of the stimate arcinoma cells and some cases of the estimate at tumor cells," Analytical opioid receptor-like (Officeroreport, 1996, 7, 72 If biosequences," Adv. Applications of the december of the decem	

TRADEWE			Sheet 17 of 23	
Form	Form PTO-1449 Modified		Serial No. 801944	
(f Patent and Publications Cited by Applicant everal sheets if necessary)	Applicant Vogeli et al.		
	epartment of Commerce t and Trademark Office	Filing Date March 8, 2001	Group Not Yet Assigned	
ОТНЕ	R DOCUMENTS (Including Author	r, Title, Date, Pertinen	t Pages, Etc.)	
GN/	Stratowa, C., et al., "Use of a luciferal linked receptors," Current Opinion in			
GO/	Strosberg, et al., "Functional expression Pharmacological Sciences, 1992, 13,		oorganisms," Trends in	
GP	Strosberg, A. D., et al., "Structure/function relationship of proteins belonging to the family of receptors coupled to GTP-binding proteins,," Eur. J. Biochem., 1991, 196, 1-10			
GQ/	Suidan, H. A., et al., "The thrombin receptor in the nervous system," Semin Thron Hemost, 1996, 22(2), 125-133			
GR /	Summers, et al., A Manual of Methods for Baculovirus Vectors and Insect Cell Culture Procedures, Texas Agricultural Experimental Station Bulletin No. 1555, 1987, 2-46			
GS /	Sutherland, E. W., et al., "Some aspe monophosphate (cyclic AMP)," Circ	_	·	
GT /	Sweetnam, P. M., et al., "The role of <i>Products</i> , 1993 , <i>56(4)</i> , 441-455	receptor binding in dru	g discovery," J. Natural	
GU	Tempest, P. R., et al., "Reshaping a hrespiratory syncytial virus infection i		-	
GV/	Trejo, J., et al., "The cloned thrombin receptor is necessary and sufficient for activation of mitogen-activated protein kinase and mitogenesis in mouse lung fibroblasts," J. Biol. Chem., 1996, 271, 21536-21541			
GW	Turgeon, V. L., et al., "Thrombin perturbs neurite outgrowth and induces apoptotic cell death in enriched chick spinal motoneuron cultures through caspase activation," <i>Neurosci</i> , 1998 , <i>18</i> (<i>17</i>), 6882-6891			
GX	Ubl, J. J., et al., "Characteristics of thrombin-induced calcium signals in rat astrocytes," <i>Glia</i> , 1997 , <i>21</i> , 361-369			
EXAMINER		DATE CONSIDERE	CD .	
		-		

	Par Sales		Sheet 18 01 23
Form 1	PTO-1449 Modified	Docket No. 00100.US1	Serial No. 09/79-5058801844
C	Patent and Publications Cited by Applicant veral sheets if necessary)	Applicant Vogeli et al.	
	epartment of Commerce and Trademark Office	Filing Date March 8, 2001	Group Not Yet Assigned
OTHE	R DOCUMENTS (Including Autho	r, Title, Date, Pertiner	t Pages, Etc.)
GY _/	Vanden Broeck, "G-protein-coupled 1996 , <i>164</i> , 189-268	receptors in insect cells	", Int. Rev. Cytology,
GZ/	Verhoeyen, M., et al., "reshaping hun activity," Science, 1988, 239, 1534-1	man antibodies: Graftin 536	g an antilysozyme
HA /	Verma, I. M., "Gene therapy," Scienare advertisements)	atific American, 1990 , 6	8-84 (pages 73-80 and 83
НВ	Walder, R. Y., et al., "Oligodeoxynucleotide-directed mutagenesis using the yeast transformation system," <i>Gene</i> , 1986 , 42, 133-139		
HC/	White, M. B., et al., "Detecting single base substitutions as heteroduplex polymorphisms," <i>Genomics</i> , 1992 , <i>12</i> , 301-306		
но/	Whiteford, H. A., et al., "Mianserin-Induced Up-Regulation of Serotonin Receptors on Normal Human Platelets in Vivo," Life Sciences, 1993, 53(4), 371-376		
HE (Wieboldt, R., et al., "Immunoaffinit screening small-molecule libraries,"	y ultrafiltration with ion Anal. Chem., 1997 , 69	n spray HPLC/MS for (9), 1683-1691
HF (Williams, M., "Receptor binding in <i>Reviews</i> , 1991 , <i>11(2)</i> , 147-184	the drug discovery prod	ess," Medicinal Research
н	Wolbring, G., et al., "Inhibition of C Biol. Chem., 1994, 269(36), 22470-	GTP-utilizing enzymes l 22472	by tyrphostins," J.
нн /	Wu, H., et al., "Building zinc finger Proc. Natl. Acad. Sci. USA, 1995, 9		therapeutic application,"
ні	Yoneda, T., et al., "The antiproliferative effects of tyrosine kinase inhibitors tyrphostins on a human squamous cell carcinoma in <i>vitro</i> and in nude mice," <i>Cancer Research</i> , 1991, 51, 4430-4435		
нј	Young, D., et al., "Isolation and Characterization of a New Cellular Oncogene Encoding a Protein with Multiple Potential Transmembrane Domains," Cell, 1986, 45, 711-719		
нқ	Zeng, Z., et al., "Cloning of a Putative Human Neurotransmitter Receptor Expression in Skeletal Muscle and Brain," <i>Biochem. & Biophys. Resear. Commun.</i> , 1998 , 242, 575-578 (Article No. RC977591)		
EXAMINER		DATE CONSIDER	RED

Sheet 19 of 23

	(,		Sheet 19 of 23		
	Form F	Modified Modified	Docket No. 00100.US1	Serial No. 09/794,038	
	Ci	Patent and Publications ted by Applicant eral sheets if necessary)	Applicant Vogeli et al.		
	U.S. De Patent	partment of Commerce and Trademark Office	Filing Date March 8, 2001	Group Not Yet Assigned	
	OTHER	NOCUMENTS (Including Author)	r, Title, Date, Pertine	nt Pages, Etc.)	
*	HL	Ausubel, F.M. et al., in Short protoc and Wiley-interscience, NY, 1992	ols in molecular biolog	y, fourth edition, Greene	
*		Ausubel, et al. (Eds.), Current Proto 1999, John Wiley & Sons, Inc.			
*	HN	Berger et al., "Guide to Molecular Cloning Techniques," in <i>Methods in Enzymology</i> , Academic Press, Inc., San Diego, CA, 1987			
*	но	Cobbold, et al., "Aequorin measurements of cytoplasmic free calcium," <i>In</i> : McCormack J.G., et al. (Eds.), <i>Cellular Calcium: A Practical Approach</i> , 1991 , Oxford, IRL Press			
*	HP [[]	Current Protocols in Molecular Bio	logy, John Wiley & So	ns, NY, 1999	
*	нод	Eisenthal, R. et al., in <i>Enzyme Assays: A Practical Approach</i> , Oxford University Press, 1992			
*	HR	Harlow, E. et al., in <i>ANTIBODIES:</i> Laboratory, Cold Spring Harbor, N	A Laboratory Manual, Y, 1988	Cold Spring Harbor	
*	HS	Haugland, Handbook of Fluorescen Eugene OR: Molecular Probes	nt probes and Research	Chemicals, 6th Ed., 1996,	
*	HT	Hendix, R.W. (ed.), Lambda II, Cold Spring Harbor Press, Cold Spring Harbor, NY, 1980			
*	HU (Hershey, A. D. (ed.), <i>The Bacteriophage Lambda</i> , Cold Spring Harbor Press, Cold Spring Harbor, NY, 1973			
*	HV/	Kruse et al. (eds.), in Tissue Cultur	e, Academic Press, 197	3	
*	HW (O'Rielly et al. (eds.), in <i>Baculovirus Expression Vectors: A Laboratory Manual</i> , W Freeman and Company, New York, 1992			
*	HX (Osol, A (ed.), in Remington's Pharmaceutical Sciences, 16th edition, 1980			
EXAM	EXAMINER DATE CONSIDERED				
DAAWHITE			-1- Office since it is		

^{*}A copy of this reference will not be forwarded to the U.S. Patent and Trademark Office since it is believed to be too voluminous and easily obtainable by the Examiner.

Sheet 20 of 23

				Sheet 20 of 20	
-	Form]	Pro-1449 Modified	Docket No. 00100.US1	Serial No. 09/72/458 501 999	
List of Patent and Publications Cited by Applicant (Use several sheets if necessary)			Applicant Vogeli et al.		
U.S. Department of Commerce Patent and Trademark Office			Filing Date March 8, 2001	Group Not Yet Assigned	
	OTHE	R DOCUMENTS (Including Author	or, Title, Date, Pertine	nt Pages, Etc.)	
*	HY		ning: A Laboratory Manual, second edition, Cold		
*	HZ	Smith et al., in Genetic Engineering	g: Principles and Metho	ds, Plenum Press, 1981	
*	IA	Stiites et al. (eds.), Basic and Clinic Publications, Los Altos, CA, 1982	nical Immunology, 4th Edition, Lange Medical		
	_				
	_				
FYAN	INER		DATE CONSIDE	RED	
LAAN				1.000	

^{*}A copy of this reference will not be forwarded to the U.S. Patent and Trademark Office since it is believed to be too voluminous and easily obtainable by the Examiner.



Sheet 21 of 23

	ME	TRANE TRANSPORT				CCI 21 01 23
]	Form F	TO-1449 Modifi	ed	Docket No. 00100.US1	Serial No. 09/794,95	801944
List of Patent and Publications Cited by Applicant (Use several sheets if necessary)				Applicant Vogeli et al.		
	U.S. Department of Commerce Patent and Trademark Office			Filing Date March 8, 2001	Group Not Yet A	ssigned
		U. S	. PATENT DO	OCUMENTS		
Examiner Initial		Document No.	Date	Name	Class	Subclass
	IB	4,343,940	08/10/82	Kreighbaum et al.	544	283
	IC	4,399,216	08/16/83	Axel et al.	435	6
	ID	4,447,608	05/08/84	Jones et al.	544	287
	IE	4,518,584	05/21/85	Mark et al.	424	85
	IF	4,683,195	07/28/87	Mullis et al.	435	6
	IG	4,683,202	07/28/87	Mullis	435	91
	IH	4,737,462	04/12/88	Mark et al.	435	253
	II	4,757,072	07/12/88	Kabbe et al.	514	257
	IJ	4,879,236	11/07/89	Smith et al.	435	235
	IK	5,202,231	04/13/93	Drmanac et al.	435	6
		FORE	IGN PATENT	DOCUMENTS		
Examiner Initial		Document No.	Date	Country	Translation YES NO	
	n. C	19845277-C1	03/09/00	DE	X (abstract only)	
	IM /	0 367 566	05/09/90	EPO		
	IN /	0 520 722	12/30/92	EPO		
	IO (0 562 734	09/29/93	EPO		
**	IP (0 566 266 A1		ЕРО		
EXAMINE	ER			DATE CONSIDE	RED	

^{**}A copy of this patent will not be forwarded to the Patent and Trademark Office as this patent is not to be published and has been withdrawn

Sheet 22 of 23

		TENT & TRADE				
Form PTO-1449 Modified List of Patent and Publications Cited by Applicant (Use several sheets if necessary)				Docket No. 00100.US1	Serial No. 09/794,838 80/944	
				Applicant Vogeli et al.		
U.S. Department of Commerce Patent and Trademark Office			Filing Date March 8, 2001	Group Not Yet Assigned		
		U. S.	PATENT DO	CUMENTS		
Examiner Initial		Document No.	Date	Name	Class	Subclass
	IQ	5,217,999	06/08/93	Levitzki et al.	514	613
	IR	5,302,606	04/12/94	Spada et al.	514	357
	IS	5,316,553	05/31/94	Kaul et al.	8	639
	IT	5,330,992	07/19/94	Eissenstat et al.	514	312
	IU	5,521,065	05/28/96	Whiteley et al.	435	6
	IV	5,585,277	12/17/96	Bowie et al.	436	518
	IW	5,837,832	12/17/98	Chee et al.	536	22.1
	IX	5,880,141	03/09/99	Tang et al.	514	339
	IY	6,147,106	11/14/00	Tang et al.	514	414
		FORE	GN PATENT	DOCUMENTS		
Examiner Initial		Document No.	Date	Country	Translation YES NO	
	IZ	91/09955	07/11/91	WO		
	JA	91/15495	10/17/91	WO		
	JB	91/18982	12/12/91	wo		
	JC	92/20642	11/26/92	wo		
	JD	92/20808 !	11/26/92	wo		
	JE	92/21660	12/10/92	wo		
	JF	93/11236	06/10/93	wo		
EXAMINER				DATE CONSIDERED		



EXAMINER

Sheet 23 of 23 Serial No. Docket No. Form PTO-1449 Modified 097294,058 00100.US1 **Applicant** List of Patent and Publications Vogeli et al. Cited by Applicant (Use several sheets if necessary) Group Filing Date U.S. Department of Commerce Not Yet Assigned March 8, 2001 Patent and Trademark Office U. S. PATENT DOCUMENTS **Document** Examiner Subclass Class Name **Date** No. Initial FOREIGN PATENT DOCUMENTS Translation Examiner NO YES **Country** Date Document No. Initial WO 02/17/94 JG (94/03427 06/09/94 WO JH / 94/12650 WO 07/07/94 94/14808 JI / WO 08/03/95 JJ . 95/20652 WO 08/01/96 96/22976 JK [WO 03/13/97 97/09433 JL WO 08/27/98 98/37177 JM / WO 04/06/00 00/18787 JN /

DATE CONSIDERED